CLOs on the Move

IO Biotech

www.iobiotech.com

 
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. Our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules. IO Biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development and several compounds finalizing preclinical phase. IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.iobiotech.com
  • 430 East 29th Street Suite 940
    New York, NY USA 10016
  • Phone: 646.440.9310

Executives

Name Title Contact Details
Devin Smith
 General Counsel and Chief Compliance Officer Profile

Similar Companies

Second Genome

Second Genome is a clinical stage company with a mission to improve human health by unlocking the full potential of the microbiome. We offer the most robust approach to microbiome drug discovery and development through the deepest understanding of how the microbiome works in human health.

R mosaic health

R mosaic health is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

United Review Services

United Review Services is a Piscataway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Escient Pharmaceuticals

Based in San Diego, we are led by an experienced team of entrepreneurs with deep roots in this region`s life sciences ecosystem and specific expertise in GPCR drug discovery and development. Escient Pharmaceuticals is supported by top-tier life-sciences investors with a proven track record for identifying and supporting successful, next-generation medicines companies.

Color

Color`s mission is to help people lead the healthiest lives that science and medicine can offer. We launched in April 2015 with a simple, affordable genetic test to help people understand their risk for hereditary cancer. In 2017, we added coverage for hereditary heart conditions.